EICHOR
● Active Not Recruiting
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
Condition: Malignant Solid Neoplasm · Refractory Cholangiocarcinoma · Refractory Malignant Solid Neoplasm · Sponsor: National Cancer Institute (NCI)
About this study
This phase II trial studies how well olaparib and ceralasertib (AZD6738) work in treating patients with IDH mutant cholangiocarcinoma or solid tumors. Cancer is caused by changes (mutations) to genes that control the way cells function. Laboratory studies have shown that olaparib and AZD6738 can shrink IDH mutant tumors or stop them from growing. Olaparib and ceralasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (13)
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | — |
| Smilow Cancer Center/Yale-New Haven Hospital | New Haven, Connecticut, United States | — |
| Yale University | New Haven, Connecticut, United States | — |
| Smilow Cancer Hospital Care Center-Trumbull | Trumbull, Connecticut, United States | — |
| UF Health Cancer Institute - Gainesville | Gainesville, Florida, United States | — |
| Northwestern University | Chicago, Illinois, United States | — |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore, Maryland, United States | — |
| Wayne State University/Karmanos Cancer Institute | Detroit, Michigan, United States | — |
| Weisberg Cancer Treatment Center | Farmington Hills, Michigan, United States | — |
| Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | — |
| UT MD Anderson Cancer Center | Houston, Texas, United States | — |
| Huntsman Cancer Institute/University of Utah | Salt Lake City, Utah, United States | — |
+ 1 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03878095